Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vaccinogen has said that its founder and CEO, Michael Hanna Jr. has acquired the rights to OncoVAX, a vaccine with the potential to prevent colon cancer from recurring in many patients.
Subscribe to our email newsletter
In the agreement, Vaccinogen has obtained exclusive license to OncoVAX Active Specific Immunotherapy as well as an important component of the product TICE BCG. The vaccine is made from the patients’s own tumor and is injected back into the patient to effect an immune response against recurrence of that cancer.
Mr. Hanna, who has been working on cancer vaccines for more than 30 years, said: “This agreement represents a major step forward in defeating cancer by increasing the body’s immunity to it.”